Xinolax DR20 mg

Xinolax DR is a serotonin-norepinephrine reuptake inhibitor (SNRI) with the following evidence-based indications:

Established / Approved Uses

• Major depressive disorder (MDD) in adults.
• Generalized anxiety disorder (GAD) in adults and in pediatric patients 7 years of age and older.
• Diabetic peripheral neuropathic pain (DPNP) in adults.
• Fibromyalgia in adults and in pediatric patients 13 years of age and older.
• Chronic musculoskeletal pain (including chronic low back pain and osteoarthritis pain) in adults.

Guideline-Supported / Adjunct Use

• Used as part of a multimodal pain-management plan for chronic musculoskeletal and neuropathic pain, often alongside non-pharmacological measures (physiotherapy, exercise, psychological therapy).

Off-Label Use (not FDA-approved, but supported by some clinical evidence)

• Stress urinary incontinence.
• Chemotherapy-induced peripheral neuropathy (pain).
• Other neuropathic pain syndromes at the discretion of the treating physician.

The exact indication and dose should always be decided by a qualified physician based on individual assessment.

Each capsule contains Duloxetine Hydrochloride equivalent to duloxetine base, commonly available in strengths of 20 mg, 30 mg, 40 mg, and 60 mg as enteric-coated pellets filled in delayed-release capsules, along with pharmaceutically acceptable excipients.

Xinolax DR is a potent, selective inhibitor of neuronal serotonin and norepinephrine reuptake, formulated as an enteric-coated, delayed-release oral capsule to reduce gastric irritation and improve tolerability. It belongs to the serotonin-norepinephrine reuptake inhibitor (SNRI) class of antidepressants and is widely used for major depressive disorder, several anxiety and pain conditions, and fibromyalgia.

Because Xinolax DR carries a boxed warning for increased suicidal thinking and behavior in children, adolescents, and young adults, and because it can cause serious hepatic, cardiovascular, and serotonergic effects, it should only be used under the supervision of a physician, with careful patient selection and monitoring.

Xinolax DR belongs to the Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) class of antidepressant/analgesic agents.

Pharmacodynamics

Duloxetine Hydrochloride works by potently and selectively inhibiting the reuptake of serotonin (5-HT) and norepinephrine (NE) at the presynaptic neuron, increasing the availability of these neurotransmitters in the central nervous system. This dual action is thought to underlie both its antidepressant/anxiolytic effect and its ability to modulate descending pain pathways, explaining its efficacy in neuropathic and musculoskeletal pain. It has minimal affinity for dopaminergic, cholinergic, histaminergic, opioid, glutamate, or GABA receptors.

Pharmacokinetics

• Absorption: Well absorbed after oral administration; peak plasma concentration reached approximately 6 hours after dosing.
• Distribution: Highly protein bound (greater than 90%).
• Metabolism: Extensively metabolized in the liver primarily via CYP1A2 and CYP2D6 enzymes.
• Elimination half-life: Approximately 12 hours (range 8–17 hours).
• Excretion: Metabolites excreted mainly in urine, with a smaller portion in feces.

Xinolax DR delayed-release capsules should be taken orally, once daily, with or without food, at approximately the same time each day. Capsules should be swallowed whole with water and must not be opened, chewed, or crushed, and the pellets inside should not be sprinkled on food or mixed with liquids, as this may affect the delayed-release coating and increase side effects. If a dose is missed, it should be taken as soon as remembered unless it is close to the next dose, in which case the missed dose should be skipped — do not double the dose. Do not stop taking Xinolax DR suddenly without consulting a physician; the dose must be tapered gradually when discontinuing.

Xinolax DR has several clinically significant drug interactions:

• Monoamine oxidase inhibitors (MAOIs): Concomitant use is contraindicated due to the risk of serotonin syndrome. At least 14 days must elapse after stopping an MAOI before starting Xinolax DR, and at least 5 days after stopping Xinolax DR before starting an MAOI.
• Other serotonergic drugs (SSRIs, other SNRIs, triptans, tramadol, lithium, St. John's Wort, fentanyl): Increased risk of serotonin syndrome when combined with Xinolax DR; use with caution and monitor closely.
• Linezolid and intravenous methylene blue: Both have MAOI activity; starting Xinolax DR in a patient already on either is contraindicated because of the serotonin syndrome risk.
• NSAIDs, aspirin, and anticoagulants (e.g., warfarin): Concomitant use with Xinolax DR may increase the risk of bleeding due to combined effects on platelet function and coagulation.
• Potent CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): Can substantially raise Xinolax DR plasma concentrations; co-administration should be avoided.
• CYP2D6 substrates/inhibitors: Xinolax DR is a moderate CYP2D6 inhibitor and can raise levels of drugs metabolized by this enzyme (e.g., tricyclic antidepressants, Type 1C antiarrhythmics); concurrent use with thioridazine is best avoided due to arrhythmia risk.
• Alcohol: May increase the risk of liver injury; patients with substantial alcohol use should avoid Xinolax DR.
• Other centrally-acting drugs/CNS depressants: Use with caution due to additive CNS effects.

Side effects of Xinolax DR range from common and mild to rare but serious.

Common Side Effects

• Nausea
• Dry mouth
• Somnolence (drowsiness)
• Constipation
• Decreased appetite
• Increased sweating (hyperhidrosis)
• Dizziness
• Fatigue
• Sexual dysfunction (delayed ejaculation, erectile dysfunction, decreased libido)

Serious Side Effects (require prompt medical attention)

• Suicidal thoughts or behavior, especially in children, adolescents, and young adults (see Precautions).
• Signs of liver injury: yellowing of skin/eyes, dark urine, right upper abdominal pain.
• Serotonin syndrome: agitation, confusion, rapid heart rate, muscle rigidity, high fever.
• Unusual bleeding or bruising.
• Severe dizziness or fainting on standing (orthostatic hypotension).
• Eye pain, vision changes, or halos around lights (possible angle-closure glaucoma).
• Seizures.
• Difficulty urinating.

Pregnancy: Xinolax DR should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus; a physician must be consulted before use. Use late in pregnancy (third trimester) has been associated with neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding, including respiratory distress, temperature instability, feeding difficulty, hypotonia, tremor, and irritability in the newborn.

Lactation: Xinolax DR passes into breast milk in small amounts. A decision should be made, in consultation with a physician, whether to discontinue breastfeeding or discontinue the drug, weighing the benefit of treatment to the mother against any potential risk to the breastfed infant.

Boxed Warning: Suicidal Thoughts and Behaviors

Xinolax DR and other antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (up to age 24) in short-term studies. Patients of all ages should be monitored closely for worsening depression, unusual changes in behavior, and suicidality, especially at the start of treatment or after a dose change. Xinolax DR is not approved for use in pediatric patients with major depressive disorder.

Hepatotoxicity

Cases of hepatic injury, including hepatocellular damage with jaundice and, rarely, fatal outcomes, have been reported. Xinolax DR should be avoided in patients with substantial alcohol use or chronic liver disease, and should be discontinued if jaundice or other evidence of significant liver dysfunction develops.

Serotonin Syndrome

A potentially life-threatening reaction can occur, particularly when Xinolax DR is combined with other serotonergic drugs (see Interactions). Symptoms include mental status changes, autonomic instability, neuromuscular abnormalities, and gastrointestinal symptoms. Xinolax DR should be discontinued immediately if serotonin syndrome is suspected.

Orthostatic Hypotension, Falls, and Syncope

These can occur, particularly during the first week of treatment or with dose increases, and are more likely in elderly patients and those on antihypertensive medication.

Increased Blood Pressure

Blood pressure should be measured before starting Xinolax DR and monitored periodically during treatment; caution is advised in patients with hypertension or cardiovascular disease.

Angle-Closure Glaucoma

Xinolax DR can cause pupillary dilation, which may precipitate an angle-closure attack in patients with anatomically narrow angles; it is contraindicated in uncontrolled narrow-angle glaucoma.

Discontinuation Symptoms

Abrupt discontinuation of Xinolax DR can cause symptoms such as dizziness, headache, nausea, paresthesia, irritability, and insomnia. The dose should always be tapered gradually rather than stopped suddenly.

Increased Bleeding Risk

Xinolax DR may increase the risk of bleeding events, particularly when combined with NSAIDs, aspirin, warfarin, or other anticoagulants (see Interactions).

Other Precautions

• Use with caution in patients with a history of seizure disorder.
• Screen for a personal/family history of bipolar disorder before starting, as antidepressants can precipitate a manic or hypomanic episode.
• Hyponatremia (including SIADH) has been reported, particularly in elderly patients; monitor for symptoms such as confusion or weakness.
• May cause urinary retention or hesitancy; use with caution in patients with predisposing conditions.

Overdose of Xinolax DR, alone or combined with other drugs or alcohol, can be serious and potentially life-threatening. Reported features of overdose include serotonin syndrome, seizures, drowsiness, vomiting, and, rarely, changes in heart rhythm.

If an overdose of Xinolax DR is suspected, seek immediate medical attention or contact emergency services / a poison control center right away. Do not attempt to manage a suspected overdose at home. Management in a hospital setting is supportive and symptomatic; there is no specific antidote.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

Xinolax DR should be avoided in patients with severe renal impairment (creatinine clearance <30 mL/min) and in those with end-stage renal disease on dialysis, as plasma concentrations of Xinolax DR and its metabolites are significantly increased.

Hepatic Impairment

Xinolax DR should be avoided in patients with chronic liver disease or hepatic impairment because of the risk of increased drug exposure and hepatotoxicity (see Precautions and Warnings).

Elderly

Elderly patients may be more sensitive to the effects of Xinolax DR, including a higher risk of hyponatremia, falls, and orthostatic hypotension. A lower starting dose (e.g., 30 mg/day for generalized anxiety disorder) is recommended in this group, with careful monitoring.

Pediatric Use

See Pediatric Uses.

The duration of treatment with Xinolax DR is individualized by the treating physician based on indication and response. For major depressive disorder, treatment is generally continued for several months after symptom improvement to reduce the risk of relapse, with periodic reassessment of the continued need for therapy. For chronic pain conditions (diabetic neuropathic pain, fibromyalgia, chronic musculoskeletal pain), treatment duration is guided by ongoing symptom control and tolerability. Treatment should never be stopped abruptly; any discontinuation must be done gradually under medical supervision (see Dosage and Administration).

Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)

Duloxetine Hydrochloride acts centrally by blocking the presynaptic reuptake transporters for serotonin and norepinephrine, thereby increasing serotonergic and noradrenergic neurotransmission in the brain and spinal cord. Enhanced noradrenergic and serotonergic tone in descending inhibitory pain pathways is believed to contribute to its analgesic effect in neuropathic and chronic pain conditions, in addition to its mood- and anxiety-modulating effects.

C

Xinolax DR has specific, age-restricted pediatric approvals and carries an important safety warning for younger patients.

• Generalized anxiety disorder: Approved for use in children and adolescents 7 years of age and older, starting at 30 mg once daily.
• Fibromyalgia: Approved for use in adolescents 13 years of age and older, starting at 30 mg once daily.
• Major depressive disorder: Xinolax DR is not approved for major depressive disorder in pediatric patients; efficacy for this indication has not been established in children and adolescents.
• Other indications (diabetic neuropathic pain, chronic musculoskeletal pain): safety and efficacy in pediatric patients have not been established.

Children, adolescents, and young adults taking Xinolax DR for any indication should be monitored closely for worsening depression, unusual behavior changes, and suicidal thinking, particularly during the first few months of treatment and after dose changes (see Boxed Warning under Precautions and Warnings).